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Abstract: Depression and smoking are highly comorbid. The vast majority of psychiatrists 
treating depressed patients do not target or treat nicotine dependence, and many inpatient 
psychiatric facilities implicitly condone smoking by providing ‘smoke breaks’. The reasons 
for failure to treat are unclear, but are probably linked to the notion that depressed smokers 
are neither willing nor able to quit, and will become more depressed if they try. We review 
the clinical evidence on depression and smoking cessation, and ﬁ  nd little support for current 
psychiatric practice. Although quitting smoking does appear to pose a risk for the development 
of depression, this risk is not clearly higher in those with a past history of depression than those 
without. Depressed smokers are as capable as nondepressed smokers of quitting smoking, and 
at least one-quarter of depressed smokers is willing to try. Sustained abstinence may even lead 
to improvement in depressive disorders. More research is needed to understand the relationship 
between depression and quitting smoking, but current clinical evidence suggests more resiliency 
among depressed smokers than common clinical wisdom would dictate.
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Introduction
Nicotine dependence is the most common psychiatric diagnosis in the United States 
(Bergen and Caporaso 1999). By some estimates, 50%–60% of patients with major 
depression also suffer from nicotine dependence (Glassman et al 1990). The prevalence 
of depression among smokers has been estimated at three times that of nonsmokers 
(Farrell et al 2001). Depression is associated with increased risk of heart disease and 
diabetes (Plante 2005); and smoking has well-known morbidity associated with it, 
including cancer, heart disease, and emphysema. Together, depression and smok-
ing may offer greater combined health risk; and women smokers may be especially 
vulnerable to this combined health risk, as they suffer from depression at a ratio of 
two to one compared with men. 
The American Psychiatric Association recommends integration of smoking 
cessation treatment with psychiatric care (APA 1996). Despite this imperative, psy-
chiatrists in everyday practice largely ignore smoking. Himelhoch and Daumit found 
that psychiatrists offered smoking cessation counseling to only 12.4% of the visits 
for smoking patients (based on 8,451 visits to 573 psychiatrists from 1992 to 1996) 
(Himelhoch and Daumit 2003). Nicotine replacement therapy was not prescribed 
at a single visit, nor the diagnosis of nicotine dependence made at any patient visit 
(Himelhoch and Daumit 2003). However, eighty percent of smokers were diagnosed 
with a depressive disorder (Himelhoch and Daumit 2003). The reasons for psychiatrists’ 
tendency to ignore nicotine dependence in patients with depressive disorders are not 
known, but probably relate to the common clinical wisdom that depressed smokers 
are neither willing nor able to quit smoking, and that any attempt at smoking cessation 
will precipitate and/or exacerbate depression.Neuropsychiatric Disease and Treatment 2007:3(4) 488
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This review examines the link between depression and 
quitting smoking, with an eye toward how the evidence 
supports or fails to support current psychiatric practice. We 
begin with a brief summary of the data on smoking cessa-
tion treatment in nondepressed smokers (ie, smokers with 
no known depressive disorder), progress to the literature on 
smoking cessation in individuals with depressive disorders, 
and ﬁ  nish with a look at treatment interventions designed 
specifically for depressed smokers (ie, smokers with a 
diagnosable depressive disorder, past or present). This review 
attempts to address the following questions: “Are depressed 
smokers willing and able to quit smoking?”, “Are depressed 
smokers versus nondepressed smokers more likely to experi-
ence depressive symptoms while trying to quit?”, and “Does 
the data support or refute common clinical practice?”.
Smoking cessation and nondepressed 
smokers 
Although recent CDC data suggest a steady decrease in 
smoking prevalence among American adults since 1993, an 
estimated 20.9% (44.5 million) are still classiﬁ  ed as current 
smokers (Maurice 2005). Several smoking cessation inter-
ventions have been introduced and approved by the Federal 
Drug Administration (FDA) over the last two decades, based 
on research conducted almost exclusively in nondepressed 
smokers. Effective treatments to date appear to consist of 
a pharmacological treatment in combination with even a 
modest psychosocial intervention (Hall et al 2002). We 
brieﬂ  y review the data on pharmacological treatments for 
smoking cessation in nondepressed smokers.
The FDA approved the ﬁ  rst nicotine replacement therapy 
(nicoretta gum) for over-the-counter (OCT) consumption in 
1996, followed closely by nicotine replacement patches and 
lozenges. In their small, recommended doses, these OCT 
therapies, in addition to the prescription only nicotine inhaler 
and nasal spray, reduce the craving and withdrawal symptoms 
often associated with smoking cessation. However, as the 
absorption methods of these therapies vary, some studies 
have shown a clinical beneﬁ  t to combining nicotine replace-
ment therapies (NRT) to achieve the most effectual treatment 
(Henningﬁ  eld et al 2005). Therefore, NRT that gradually 
releases nicotine (ie, the nicotine patch) in combination with 
an acute release therapy (ie, gum, lozenges, inhaler, and nasal 
spray) provides treatment in which long-term and short term 
cravings and withdrawal symptoms are better addressed 
(Sweeney et al 2001).
In addition to nicotine replacement therapies, pharma-
cological treatments are also recommended during smoking 
cessation therapy, and the FDA has approved two ﬁ  rst line 
pharmacological treatments for this purpose. The first, 
bupropion hydrochloride, is believed to restrain the reuptake 
of norepinephrine and dopamine with minimal side effects 
and a high rate of tolerability (Kotlyar and Hatsukami 2002). 
Although initially promoted for its antidepressant qualities, 
extensive research has consistently shown bupropion’s 
efﬁ  cacy as a smoking cessation aid as well (Richmond and 
Zwar 2003). Hurt and colleagues (1997) published the ﬁ  rst 
controlled trial to examine the efﬁ  cacy of bupropion as a 
treatment for nicotine dependence (Hurt et al 1997). In that 
trial, 615 nondepressed smokers were randomly assigned to 
placebo or three regimens of bupropion (100 mg, 150 mg, 
300 mg). At 12 month follow-up, abstinence rates were 
as follows: placebo 12.4%; buproprion 100 mg 19.6%; 
bupropion 150 mg 22.9%; buproprion 300 mg 23.1%. 
In perhaps the first study to combine NRT with an 
antidepressant medication, a trial by Jorenby and colleagues 
(1999), conducted under the auspices of the manufacturer, 
compared placebo with bupropion (300 mg), nicotine patch 
(21 mg), and nicotine patch (21 mg) + bupropion (300 mg). 
Eight Hundred and thirty-nine nondepressed smokers were 
randomized. Treatment lasted seven weeks with a 2-week 
tapering phase. Participants met weekly for testing and to 
receive counseling interventions. Point prevalence abstinence 
rates at 12-month follow-up were as follows: placebo 15.6%; 
nicotine patch 16.4%; bupropion 30.3%; bupropion + nicotine 
patch 35.5%. These findings suggest once again that a 
combination of smoking cessation interventions produce 
more signiﬁ  cant abstinence rates (Jorenby et al 1999). 
The nicotinic acetylcholine receptor partial agonist 
varenicline tartrate is the second and most recently FDA 
approved pharmacological treatment for smoking cessation. 
In two randomized, double-blind, placebo-controlled clinical 
trails conducted by Gonzales and colleagues (2006) and 
Jorenby and colleagues (2006), varenicline was compared 
with bupropion and placebo to determine its efﬁ  cacy. Over-
all, the abstinence rates from both studies demonstrated that 
varenicline was more effective than both bupropion and pla-
cebo at short-term and long-term time follow-up (Gonzales 
et al 2006; Jorenby et al 2006). 
In the trial conducted by Jorenby and colleagues 
(2006), 1,027 nondepressed smokers received brief 
smoking cessation counseling (10 min) per US Public 
Health Services guidelines, in combination with one of the 
following: varenicline (titrated to 1 mg twice per day), bupro-
pion sustained release (SR) (titrated to 150 mg twice per day), 
or placebo, during the 12 week treatment period, followed Neuropsychiatric Disease and Treatment 2007:3(4) 489
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by 40 weeks nonpharmacological follow-up. The four week 
continuous abstinence rates for weeks 9 through 12 were 
as follows: varenicline 43.9%, bupropion SR 29.8%, and 
placebo 17.6%. The continuous abstinence rates for weeks 
9 through 52 were as follows: varenicline 23%, bupropion 
SR 14.6%, and placebo 10.3% (Jorenby et al 2006).
Similarly, Gonzales and colleagues (2006) enrolled 1,025 
nondepressed smokers in their randomized, double-blind, 
placebo-controlled study. In this trial, participants were 
randomly assigned to receive brief smoking cessation 
counseling (10 min) per US Public Health Services guide-
lines, as well as varenicline (titrated to 1 mg twice per day), 
bupropion SR (titrated to 150 mg twice per day), or placebo 
during the 12 week treatment period, followed by 40 weeks 
nonpharmacological follow-up. The four week abstinence 
rates for weeks 9 through 12 were as follows: varenicline 
44.0%, bupropion SR 29.5%, and placebo 17.7%. The 
continuous abstinence rates for weeks 9 through 52 were 
as follows: varenicline 21.9%, bupropion SR 16.1%, and 
placebo 8.4% (Gonzales et al 2006). 
Nortriptyline has been endorsed by the US clinical 
practice guideline and the agency for health research quality 
(AHRQ) as a second-line smoking cessation therapy 
(Henningﬁ  eld et al 2005), although it is not FDA approved 
as such. Hall and colleagues (1998) combined the tricyclic 
antidepressant nortriptyline or placebo with an intensive, 
clinic-based behavioral treatment program and found the 
64-week continuous abstinence rate produced by nortriptyline 
was double that for placebo (24% vs. 12%). Nortriptyline 
was also superior to placebo in a second study conducted by 
Prochazka and colleagues (1998), although the 6-mo point 
prevalence abstinence rates for both active and placebo 
conditions were low (nortriptyline 14%; placebo 3%). 
Perhaps in light of the promising results produced by 
the antidepressants bupropion and nortriptyline, researchers 
have studied the effectiveness of other antidepressants for 
smoking cessation as well. In a recent study by Niaura 
and colleagues (2002), 989 nondepressed smokers were 
assigned to a 10-week trial of the serotonin reuptake inhibitor 
ﬂ  uoxetine or placebo coupled with a clinic-based, individu-
alized behavioral intervention. Mean abstinence rates were 
not reported but survival analysis suggested that ﬂ  uoxetine 
resulted in an improved response-to-treatment. Interestingly, 
ﬂ  uoxetine plasma levels were associated with survival time. 
However, in a recent literature review of multiple studies on 
this subject, Hughes and colleagues (2004) found very little 
evidence to suggest a long-term beneﬁ  t of serotonin reuptake 
inhibitors, atypicals, and monoamine oxidase inhibitors as 
smoking cessation aids in nondepressed populations. In turn, 
these data imply that the mechanism by which bupropion and 
nortriptyline function as smoking cessation aids is indepen-
dent of their antidepressant qualities. 
Smoking cessation and depressed 
smokers
Depressed smokers are an understudied population. They 
are typically excluded from smoking cessation trials. Most 
studies designed speciﬁ  cally to examine the effectiveness of 
a given treatment for smoking cessation, exclude individuals 
with depression (Hurt et al 1997; Jorenby et al 1999; Jack et al 
2003). The paucity of clinical research in this area, despite the 
strong epidemiologic link between depression and smoking, 
is likely related to the premise that depressed smokers will 
not accept or tolerate smoking cessation interventions. 
Are depressed smokers willing to stop smoking? 
Prochaska and colleagues (2004) showed that in fact about 
a fourth of depressed smokers surveyed were eager to quit 
smoking, and were willing to take action to quit within 
30 days. This study also found that depression severity and 
history of depression recurrence were not related to willing-
ness to try to quit smoking among depressed outpatients. 
Haug and colleagues (2005) showed that 53 of 154 depressed 
smokers were willing to embark on a smoking cessation 
treatment plan that included behavioral counseling, nicotine 
patch, and bupropion. Haug and colleagues also found that 
severity of depression symptoms and depression history were 
unrelated to acceptance of smoking cessation treatment. On 
the other hand, few chronic psychiatric inpatients are ready 
to try to quit smoking (Hall et al 1995).
Are depressed smokers able to stop smoking? Data are 
mixed on the effects of depression severity or history of 
depression on quit rates. Anda and colleagues (1990) showed 
in an epidemiologic, cross-sectional study, that smokers 
with higher depression scores at the start of smoking cessa-
tion treatment were less likely to have quit eight years later 
than smokers not depressed at baseline (10% vs 18% quit). 
However, John and colleagues (2004), in a cross-sectional 
analysis of 4,075 smokers with past (lifetime) or current 
(12-month) diagnosis of depression, showed no difference 
in smoking cessation three years later compared to those 
without a mood disorder. A recent meta-analysis by Hitsman 
and colleagues (2003), looked at 15 published studies and 
found no difference in either short-term (less than 3 months) 
or long-term (greater than 6 months) abstinence rates between 
smokers positive versus negative for history of depression. 
A study of the effect of baseline depressive symptoms Neuropsychiatric Disease and Treatment 2007:3(4) 490
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on smoking outcomes in 600 African American smokers, 
found that baseline depression also did not correlate with 
cessation rates at study endpoint (Catley et al 2005). The 
preponderance of the evidence implies that depression does 
not adversely affect smoking quit rates; ie, smokers with 
depressive disorders are able to quit smoking at the same 
rates as nondepressed smokers.
The progression of depressive symptoms over the course of 
smoking cessation treatment, appears to be a more consistent 
negative correlate of quitting smoking. Killen and colleagues 
(1996) have shown that worsening of depression during 
smoking cessation treatment, even in subjects who do not 
meet criteria for major depression at start of treatment, pre-
dicts a worse outcome in quitting smoking. Others have also 
found that individuals who become depressed while trying 
to quit smoking, are less likely to be successful at quitting 
(Cinciripini et al 2003; Levine et al 2003; Catley et al 2005). 
Burgess and colleagues (2002) have demonstrated that a 
delayed increase in depressive symptoms during smoking 
cessation treatment, as oppose to an initial short-lived increase 
or a steady decrease, is associated with lower quit rates. This 
is an interesting ﬁ  nding, implying that dysphoria in the acute 
withdrawal period may be different from dysphoria that begins 
or progresses after acute withdrawal has abated. 
In summary, smoking quit rates are not clearly associated 
with prior history of depression, depressive symptoms at the 
start of smoking cessation treatment, or even necessarily 
brieﬂ  y depressed mood in the acute withdrawal period. How-
ever, the trajectory of mood symptoms over the course of 
smoking cessation treatment does appear to impact quit rates: 
namely, worsening of depression after quitting appears to be 
a risk-factor for poor smoking outcomes. So who is likely to 
get depressed while quitting? Common clinical wisdom holds 
that individuals with history of depression are particularly 
vulnerable to worsening mood symptoms during smoking 
cessation. What is the evidence to support the notion that 
depressed smokers are more vulnerable to depression while 
quitting than nondepressed smokers? 
A study by Glassman and colleagues (2001) examined 76 
smokers with a past history of major depressive disorder, 
all euthymic and off of antidepressant medication at the 
start of smoking cessation treatment, in order to determine 
the rates of recurrent depression in abstainers versus 
nonabstainers. Subjects were enrolled in a 2-month smok-
ing cessation trial, and recurrence of major depression 
was assessed by structured clinical interviews at three 
and six month intervals. Thirteen of 42 successful ab-
stainers had a recurrence of major depression; whereas 
two of 34 smokers had a recurrence of major depression. 
The findings demonstrate that depressed smokers who 
quit smoking are more likely to relapse to depression 
than depressed smokers who keep smoking; but only a 
minority of depressed smokers will get depressed. The 
study did not include a comparison group of nondepressed 
smokers, and so does not address the question of whether 
depressed smokers are at higher risk for depression than 
nondepressed smokers during quitting. 
Covey and colleagues (1997) compared the rates of 
occurrence of major depression with smoking cessation, 
among smokers with no prior diagnosis of depression, 
smokers with one prior major depressive episode, and 
smokers with recurrent major depressive disorder (Covey 
et al 1997). Smokers who succeeded in abstaining from 
cigarettes for a 10-week smoking cessation program, were 
followed up three months after quitting (N = 126), and 
assessed for a major depressive episode using DSM-III-R 
criteria. Two of 91 subjects with no history, four of 
24 subjects with past single major depression, and three 
of 10 subjects with past recurrent major depression, de-
veloped a major depressive episode by 3-month follow-
up. In the absence of a comparison between those who 
did and did not successfully quit smoking, the results of 
the study are difficult to interpret. Those who continued 
smoking might have relapsed to major depression at the 
3-month follow-up at the same rates as those who quit, 
given the recurrent nature of depressive disorders, par-
ticular in the absence of treatment. Nonetheless, the study 
does provide some preliminary evidence that those with 
prior depressive disorders, who quit smoking, are more 
likely to have a major depressive episode in the months 
following smoking cessation, than those with no prior 
depression history. 
Even more remarkable is the apparent resiliency of 
smokers with depressive disorders in the face of smoking 
cessation, a signiﬁ  cant physical and psychological stressor. 
The covey study found that 24 of 34 smokers, more than two-
thirds the sample with a prior diagnosis of major depression, 
did not have a recurrence of major depression after quitting 
smoking, even without antidepressant medication or other 
apparent intervention. Two of the subjects who did have a 
recurrence of depression, experienced depressive symptoms 
for only two days before restarting effective antidepressant 
therapy. 
In a study by Covey et al, placebo was compared with 
bupropion for smoking cessation treatment (N = 429). 
Depressive symptoms were measured at weeks 8 and 12. Neuropsychiatric Disease and Treatment 2007:3(4) 491
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Changes in depressive symptoms were measured at these 
endpoints, and did not differ for those with and without a 
past history of depression (Cox et al 2004). 
The clinical studies reviewed above have included 
depressed smokers who were euthymic (ie, not depressed) 
at the initiation of smoking cessation treatment, and not on 
antidepressant therapy. Presumably, these individuals had a 
less severe form of depression, since they were able to be 
well without treatment for depression for some period of time. 
To our knowledge, smokers who are depressed at baseline, 
on or off medication, and smokers with more severe forms 
of depression, have not been included in smoking cessation 
studies comparing clinical outcomes with nondepressed 
smokers. 
Is there any evidence that stopping smoking actually 
improves depression? Burgess and colleagues (2002) found 
that of 163 smokers with a past history of depression, 40% 
experienced an increase in depression symptoms during 
quitting, and 47% experienced a decrease in depression 
symptoms during quitting. In a national household survey 
on drug abuse (N = 13,827), although current smokers were 
found to be at highest odds for suffering from depression, 
followed by former smokers, followed by nonsmokers; 
odds of depression were lower with more elapsed time 
since last smoking (Martini et al 2002). Thorsteinsson and 
colleagues (2001) used nicotine replacement therapy in 
smokers who were depressed at the initiation of smoking 
cessation treatment, independent of past history of depres-
sion, and examined both smoking and mood outcomes. One 
patient in the placebo group (N = 20), and no patients in 
the nicotine group (N = 18), became more depressed; and 
there was a trend for improved mood symptoms in those 
subjects who remained abstinent from cigarettes for 29 days. 
This study was limited by small sample size. A study by 
Kahler and colleagues (2002) looked prospectively at 179 
smokers with a history of major depression, and found 
that continuous abstinence was associated with short- and 
long-term reductions in depressive symptoms (Kahler et al 
2002). Although limited, these data suggest that abstinence 
may contribute to mood gains.
Improved mood with sustained abstinence from ciga-
rettes may be related to brain serotonin levels. A study by 
Malone and colleagues (2003) showed an inverse relationship 
between amount of cigarettes smoked and serotonin function, 
as measured by fenﬂ  uramine challenge tests and cerebro-
spinal ﬂ  uid levels of 5-hydroxyindoleacetic acid. Another 
potential explanation for improved mood with smoking 
cessation is a decrease in hypercholinergic neurotransmission 
at the nicotinic acetylcholine receptors (nAChR) (Shytle 
et al 2002).
Combined treatments for smoking 
cessation and depression
Based on the evidence reviewed above, if mood symptoms 
could be effectively targeted during smoking cessation treat-
ment, then depressed smokers, or more accurately depressed 
quitters, would have a better chance at cessation. Several 
studies have researched smoking cessation interventions 
designed speciﬁ  cally for depressed smokers. We examine 
these sparse data below.
A study in African American smokers demonstrated beneﬁ  t 
of bupropion on mood during smoking cessation treatment 
(Ahluwalia et al 2002); and a follow-up study suggested 
that bupropion may facilitate smoking cessation in part by 
reducing depressive symptoms (Catley et al 2005). However, 
even in this study, the authors concluded that bupropion’s 
primary mechanism of action is not related to its antidepressant 
efﬁ  cacy, even among the more depressed smokers. 
In a group of sub-clinically depressed smokers, Lerman 
and colleagues (2004) found that highly nicotine dependent 
smokers (score of six or more on the fagerstrom test for nico-
tine dependence) receiving bupropion 300 mg for smoking 
cessation, had a significant improvement in depressive 
symptoms compared to highly nicotine dependent smokers on 
placebo. Once the smoking cessation treatment protocol was 
over and bupropion/placebo discontinued, those who stopped 
bupropion got signiﬁ  cantly more depressed than those who 
stopped placebo. The effect of bupropion on mood held true 
only for the high dependence nicotine group, not the low 
dependence group. This study implies that highly dependent 
smokers are more likely to have a positive mood response 
to bupropion, and may need to continue bupropion longer 
than the usual 10–12 week recommended course. Whether 
the bupropion is directly mediating mood, or mediating 
some component of nicotine dependence affecting mood, 
is unclear. 
Brown and colleagues (2001) found that for a subset 
of smokers with past recurrent major depression and high 
nicotine dependence, a cognitive behavioral therapy directed 
speciﬁ  cally for depressed mood led to higher abstinence 
rates than standard CBT for smoking cessation. A study by 
Haas and colleagues (2004) also supports the use of CBT 
over health education in smokers with a past history of major 
depression. 
Covey and colleagues (2002) designed a study look-
ing at the use of sertraline, a serotonergic antidepressant, Neuropsychiatric Disease and Treatment 2007:3(4) 492
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speciﬁ  caly in the treatment of depressed smokers. Smokers 
with a history of major depressive disorder (N = 134) and 
varying degrees of depressive symptomatology at baseline, 
were randomized to receive sertraline or placebo over a 9 
week period, combined with intensive individual weekly 
counseling. Sertraline proved to be more effective than 
placebo in ameliorating the acute withdrawal symptoms of 
irritability, anxiety, and craving, but no more effective than 
placebo in terms of abstinence rates. 
The limited data suggest that smoking cessation treat-
ments modiﬁ  ed to target depressed mood, may improve 
abstinence rates for certain subpopulations of smokers. 
The interplay between mood and degree of nicotine depen-
dence may be an important predictor of the progression of 
depression while quitting (Pomerleau et al 2005). Highly 
nicotine dependent smokers may have a more profound and 
protracted withdrawal, which can mimic and possibly even 
lead to depression; and/or stopping smoking may unmask an 
underlying depressive disorder in individuals who were not 
previously symptomatic. 
Conclusions and future directions
Most psychiatrists do not address or treat smoking in 
depressed patients, presumably because they anticipate that 
depressed smokers will be unwilling to quit, unable to quit, 
and that smoking cessation will cause or exacerbate depres-
sive symptoms. The evidence does not clearly support this 
bias. At least a quarter of nonhospitalized psychiatric patients 
with a diagnosis of a depressive disorder are willing to try and 
quit smoking. Past history of depression, and even depres-
sive symptoms at the start of smoking cessation treatment, 
do not consistently negatively impact quit rates. Depressed 
smokers may be at higher risk to experience depression 
with smoking cessation than nondepressed smokers, but the 
data is equivocal. Abstinence from cigarettes for prolonged 
periods may be associated with a decrease in depressive 
symptomatology. 
A minority of smokers will enter a major depressive epi-
sode during or shortly after quitting smoking. The trajectory 
of mood symptoms after quitting appears to be a sensitive 
predictor of relapse. More research is needed to explore 
which individuals will become depressed after quitting; and 
what treatment methods should be used to target smoking 
cessation-induced depression. More research on the impact 
of mood at baseline, including severity and specificity 
of depressive symptoms, would help clarify which types of 
smokers are most vulnerable to depression during smoking 
cessation. Future studies should also try to elucidate what 
other variables besides mood contribute to poor mood 
trajectory and lower cessation rates. The data point toward 
nicotine dependence as an important contributing variable: 
highly nicotine dependent smokers are potentially at higher 
risk for depression and relapse, but also more responsive to 
bupropion. Preliminary evidence supports the development of 
speciﬁ  c smoking cessation treatments tailored for depression, 
over standard smoking cessation therapies. 
A review of the evidence highlights the resiliency of 
depressed smokers in the face of smoking cessation, contrary 
to common clinical wisdom. When one considers the potential 
gain in offering smoking cessation treatment to individuals 
with depressive disorders, including the potential for decreased 
morbidity and mortality from both nicotine dependence and 
depression; the risk of depression may well be worth taking, 
and certainly worth discussing with patients. And who better 
to provide smoking cessation treatment, than psychiatrists and 
other mental health care practitioners who are experienced in 
the treatment of depressive disorders?
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